Published in J Urol on January 01, 2006
Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract (2008) 2.66
α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics. Br J Clin Pharmacol (2011) 0.93
Actions of two main metabolites of propiverine (M-1 and M-2) on voltage-dependent L-type Ca2+ currents and Ca2+ transients in murine urinary bladder myocytes. J Pharmacol Exp Ther (2007) 0.88
Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.85
Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M1-M5 receptor single knockout mice. Br J Pharmacol (2009) 0.83
Similarities and differences in the autonomic control of airway and urinary bladder smooth muscle. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.82
Anticholinergic effects of cis- and trans-isomers of two metabolites of propiverine. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.81
Extending the rationale of combination therapy to unresponsive erectile dysfunction. Rev Urol (2007) 0.80
The muscarinic receptor antagonist propiverine exhibits α(1)-adrenoceptor antagonism in human prostate and porcine trigonum. World J Urol (2011) 0.79
Characterization of bladder selectivity of antimuscarinic agents on the basis of in vivo drug-receptor binding. Int Neurourol J (2012) 0.75
The effects of tolterodine on anterior segment and choroidal thickness in patients with overactive bladder syndrome. Ther Adv Urol (2017) 0.75
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med (2011) 4.51
Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology (2006) 2.63
EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer (2008) 2.40
Expression and functional role of β3 -adrenoceptors in the human ureter. Int J Urol (2013) 2.13
Laparoscopic simultaneous bilateral adrenalectomy for testosterone-secreting bilateral adrenal tumors. Int J Urol (2013) 2.03
Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol (2009) 2.03
Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice. J Clin Invest (2010) 1.83
Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol (2006) 1.78
The TRPV4 cation channel mediates stretch-evoked Ca2+ influx and ATP release in primary urothelial cell cultures. J Biol Chem (2009) 1.61
Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder. BJU Int (2007) 1.61
Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int (2014) 1.57
PIK3CA mutation and amplification in human lung cancer. Pathol Int (2007) 1.55
Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. Int J Urol (2010) 1.51
Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients. Cardiology (2009) 1.49
Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation. Biol Pharm Bull (2006) 1.48
Pharmacological effect of TRK-380, a novel selective human β3-adrenoceptor agonist, on mammalian detrusor strips. Urology (2011) 1.47
Aggressive angiomyxoma in the scrotum expressing androgen and progesterone receptors. Int J Urol (2003) 1.47
Resistive index as risk factor for acute urinary retention in patients with benign prostatic hyperplasia. Urology (2010) 1.46
The value of power Doppler imaging to predict the histologic components of benign prostatic hyperplasia. Prostate (2002) 1.42
Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck. Oral Oncol (2008) 1.41
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol (2008) 1.41
Arteriosclerosis related factors had no clinical significant correlation with resistive index in symptomatic benign prostatic hyperplasia. Urology (2010) 1.39
Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res (2004) 1.39
BK virus nephropathy: clinical experience in a university hospital in Japan. Int J Urol (2009) 1.38
Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm (2011) 1.38
Mast cell regulation of epithelial TSLP expression plays an important role in the development of allergic rhinitis. Eur J Immunol (2008) 1.32
Langerhans cells are critical in epicutaneous sensitization with protein antigen via thymic stromal lymphopoietin receptor signaling. J Allergy Clin Immunol (2012) 1.28
Clinical guidelines for overactive bladder. Int J Urol (2009) 1.27
Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer (2011) 1.26
Spontaneous rupture of the urinary bladder presenting as oliguric acute renal failure. Intern Med (2006) 1.26
Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat (2006) 1.25
Bladder Cancer Working Group report. Jpn J Clin Oncol (2010) 1.21
Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone. Hum Mutat (2008) 1.17
Laparoscopic adrenalectomy for large adrenal tumors. J Endourol (2005) 1.16
Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol (2005) 1.15
Prevalence of renal cell carcinoma: a nation-wide survey in Japan, 2002. Int J Urol (2007) 1.14
Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol (2008) 1.13
Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure. Biochem Biophys Res Commun (2011) 1.13
Nitric oxide-mediated regulation of connexin43 expression and gap junctional intercellular communication in mesangial cells. J Am Soc Nephrol (2004) 1.12
Outline of JUA clinical guidelines for benign prostatic hyperplasia. Int J Urol (2011) 1.11
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol (2013) 1.10
Differential expression profile of cold (TRPA1) and cool (TRPM8) receptors in human urogenital organs. Urology (2008) 1.10
TWEAK/Fn14 interaction stimulates human bronchial epithelial cells to produce IL-8 and GM-CSF. Biochem Biophys Res Commun (2004) 1.09
Mycolyltransferase-mediated glycolipid exchange in Mycobacteria. J Biol Chem (2008) 1.09
Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. Prostate Int (2014) 1.08
Endovascular treatment of ureteroarterial fistulas with stent-grafts. Radiat Med (2008) 1.08
Transient receptor potential channel A1 involved in sensory transduction of rat urinary bladder through C-fiber pathway. Urology (2007) 1.07
LVQ-SMOTE - Learning Vector Quantization based Synthetic Minority Over-sampling Technique for biomedical data. BioData Min (2013) 1.06
Suppression of NF-kappaB by cyclosporin a and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response. J Immunol (2009) 1.05
Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck. Cancer Sci (2012) 1.05
Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the overactive bladder symptoms score. Urology (2010) 1.05
Identification of mutations in the prostaglandin transporter gene SLCO2A1 and its phenotype-genotype correlation in Japanese patients with pachydermoperiostosis. J Dermatol Sci (2012) 1.05
Voiding and incontinence frequencies: variability of diary data and required diary length. Neurourol Urodyn (2002) 1.04
Prediction of postoperative renal function by preoperative serum creatinine level and three-dimensional diagnostic image reconstruction in patients with renal cell carcinoma. Urology (2004) 1.02
Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice. Brain Res Mol Brain Res (2005) 1.02
Clinical guideline for male lower urinary tract symptoms. Int J Urol (2009) 1.02
Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study. Urology (2011) 1.01
Prostaglandin I2-IP signaling promotes Th1 differentiation in a mouse model of contact hypersensitivity. J Immunol (2010) 1.01
Flaky tail mouse denotes human atopic dermatitis in the steady state and by topical application with Dermatophagoides pteronyssinus extract. Am J Pathol (2010) 1.01
Rapid, transient induction of ER stress in the liver and kidney after acute exposure to heavy metal: evidence from transgenic sensor mice. FEBS Lett (2007) 0.99
Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer. Urology (2010) 0.99
Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma. Cancer Sci (2007) 0.98
Overexpression of epithelial sodium channels in epithelium of human urinary bladder with outlet obstruction. Urology (2004) 0.98
Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther (2005) 0.97
Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. J Thorac Oncol (2012) 0.97
The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis (2003) 0.96
Primary tumor induces sentinel lymph node lymphangiogenesis in oral squamous cell carcinoma. Oral Oncol (2010) 0.95
Primary hyperoxaluria type 1 in Japan. Am J Nephrol (2005) 0.95
Successful outcomes using combination therapy of interleukin-2 and interferon-alpha for renal cell carcinoma patients with lung metastasis. Jpn J Clin Oncol (2010) 0.95
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clin Cancer Res (2010) 0.95
Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability. J Pharm Sci (2010) 0.94
Resistance to apoptosis-inducing stimuli in CD44+ head and neck squamous cell carcinoma cells. Head Neck (2011) 0.94
Examination, diagnosis and classification for Japanese allergic rhinitis: Japanese guideline. Auris Nasus Larynx (2012) 0.94
Effects of a novel beta(3)-adrenoceptor agonist, AJ-9677, on relaxation of the detrusor muscle: an in vitro study. Int J Urol (2008) 0.93
Detection of transcript for brain-type fatty Acid-binding protein in tumor and urine of patients with renal cell carcinoma. Urology (2007) 0.93
Continuous, noninvasive monitoring of local microscopic inflammation using a genetically engineered cell-based biosensor. Lab Invest (2005) 0.93
Metastatic uveal tumor secondary to testicular choriocarcinoma. Jpn J Ophthalmol (2004) 0.93
Cordycepin (3'-deoxyadenosine) inhibits the growth of B16-BL6 mouse melanoma cells through the stimulation of adenosine A3 receptor followed by glycogen synthase kinase-3beta activation and cyclin D1 suppression. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.93
Rho-mDia1 pathway is required for adhesion, migration, and T-cell stimulation in dendritic cells. Blood (2010) 0.93
Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Urology (2010) 0.92
Tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a phase 1 study in Japanese patients with previously treated non-small-cell lung cancer. J Thorac Oncol (2015) 0.92
Case of intractable ophiasis type of alopecia areata presumably improved by fexofenadine. J Dermatol (2012) 0.92
Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck. Head Neck (2011) 0.92